In this community-based study, we found that cognitively intact older adults with higher levels of p-tau181, p-tau217, NfL, and GFAP face a higher risk of developing both all-cause and Alzheimer's dementia than do those with lower biomarker levels, showing a non-linear dose–response relationship. This evidence concerns the gene GFAP and Alzheimer disease.